285 related articles for article (PubMed ID: 32543358)
1. Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies.
Peng Y; Tao H; Gao Y; Yang Y; Chen Z
Curr Top Med Chem; 2021; 21(5):404-425. PubMed ID: 32543358
[TBL] [Abstract][Full Text] [Related]
2. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
3. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
[TBL] [Abstract][Full Text] [Related]
6. A systematic analysis of FDA-approved anticancer drugs.
Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
[TBL] [Abstract][Full Text] [Related]
7. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
[TBL] [Abstract][Full Text] [Related]
8. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
Thein KZ; Lemery SJ; Kummar S
Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
[TBL] [Abstract][Full Text] [Related]
9. Site-agnostic biomarker-guided oncology drug development.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):583-592. PubMed ID: 31813299
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract][Full Text] [Related]
11. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
Nakayama H; Matsumaru N; Tsukamoto K
Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
[TBL] [Abstract][Full Text] [Related]
12. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E
Clin Cancer Res; 2019 Jun; 25(11):3210-3219. PubMed ID: 30670489
[TBL] [Abstract][Full Text] [Related]
13. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J; Chen EY; Prasad V
JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
[TBL] [Abstract][Full Text] [Related]
15. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
Barone A; Casey D; McKee AE; Reaman G
Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
[TBL] [Abstract][Full Text] [Related]
16. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.
Gershkovich P; Platt J; Knopf J; Tasoulis MK; Shi W; Pusztai L; Hatzis C
JCO Clin Cancer Inform; 2018 Dec; 2():1-13. PubMed ID: 30652574
[TBL] [Abstract][Full Text] [Related]
17. Analysis of FDA approvals of targeted anticancer combination regimens.
Brown VT; Cho V; Parkey S
Am J Health Syst Pharm; 2017 Dec; 74(23):1938-1942. PubMed ID: 29167134
[No Abstract] [Full Text] [Related]
18. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
19. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.
Dy GK; Nesline MK; Papanicolau-Sengos A; DePietro P; LeVea CM; Early A; Chen H; Grand'Maison A; Boland P; Ernstoff MS; Edge S; Akers S; Opyrchal M; Chatta G; Odunsi K; Pabla S; Conroy JM; Glenn ST; DeFedericis HT; Burgher B; Andreas J; Giamo V; Qin M; Wang Y; Kanehira K; Lenzo FL; Frederick P; Lele S; Galluzzi L; Kuvshinoff B; Morrison C
BMC Med Inform Decis Mak; 2019 Jan; 19(1):14. PubMed ID: 30658646
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
